Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Immunomodulators Market: By Product Immunostimulants ) By Application and Geography
Immunomodulators Market: By Product Immunostimulants ) By Application and Geography
Immunomodulators Market size was valued at US$ 192.6 million in 2023 and is poised to grow at a CAGR of 5.8% over 2024-2030. The global market provides a detailed overview of the immunomodulators market and that can be segmented by product and application. By product, the immunomodulators market has been segmented into immunosuppressants and immunostimulants. The immunosuppressants segment is likely to be the largest and fastest-growing segment in terms of product. The immunosuppressants segment is further segmented into antibodies, calcineurin inhibitors, glucocorticoids, and antimetabolites. Immunostimulants is segregated into vaccines and antibodies. Based on application, the immunomodulators market is segmented into oncology, respiratory, and HIV. Among these, the oncology segment is expected to have the fastest-growing market during the forecast period.
Study Period
2024-2030Base Year
2023CAGR
5.8%Largest Market
North AmericaFastest Growing Market
Asia Pacific
The rising prevalence of chronic diseases like as asthma, cancer, allergy ailments, and multiple sclerosis is a major contributor to the global Immunomodulators Market's expansion. In addition, the increased use of early immunomodulator therapy for the treatment of Crohn's disease is boosting the market's growth. The availability of significant unmet clinical requirements in the treatment of immunological illnesses, such as rheumatoid arthritis, is driving this vertical's expansion.
By region, the North American market is expected to witness the highest market share during the forecast period. Their dominance is explained by the presence of a large ill population in this area. As a result, growing end-user demand for immunomodulator-based treatment and the high therapy costs associated with treating multiple sclerosis with these immunotherapeutic drugs are likely to drive revenue growth in this category. Due to the availability of supportive government programs and improved awareness among end-users, immunomodulatory drugs are in high demand.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2024-2030 |
|
Market Size in 2023 |
US$ 192.6 million |
|
Market CAGR |
5.8% |
|
By Product |
|
|
By Application |
|
|
By Region |
|
Download Free Sample Report
Immunomodulators market size was valued at US$ 192.6 million in 2023 and is expected to grow at a CAGR of 5.8% during the forecast period 2024 to 2030.
The major players in the global Immunomodulators Market are Hoffmann-La Roche Ltd (Basel, Switzerland), Novartis AG (Basel, Switzerland), Biogen (Massachusetts, U.S.), Teva Pharmaceutical Industries Ltd. (Petah Tikva, Israel), Amgen, Inc (California, U.S.), Bristol-Myers and Squibb Company (New York, U.S), Merck Sharp and Dohme Corp. (New jersey, U.S) and Eli Lilly and Company (Indiana, U.S).
Asia Pacific is the fastest-growing region for Immunomodulators Market
| 1. Executive Summary |
| 2. Global Immunomodulators Market Introduction |
| 2.1. Global Immunomodulators Market - Taxonomy |
| 2.2. Global Immunomodulators Market -Definitions |
| 2.2.1. By Product |
| 2.2.2. By Application |
| 2.2.3. By Region |
| 3. Global Immunomodulators Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Global Immunomodulators Market Dynamic Factors - Impact Analysis |
| 3.6. Global Immunomodulators Market - Competition Landscape |
| 4. Global Immunomodulators Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Immunomodulators Market, By Product, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.1. Immunosuppressants |
| 5.1.1. Antibodies |
| 5.1.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.1.3. Market Opportunity Analysis |
| 5.1.2. Calcineurin inhibitors |
| 5.1.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.2.3. Market Opportunity Analysis |
| 5.1.3. Glucocorticoids |
| 5.1.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3.3. Market Opportunity Analysis |
| 5.1.4. Antimetabolites |
| 5.1.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.4.3. Market Opportunity Analysis |
| 5.1.5. Others |
| 5.1.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.1.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.5.3. Market Opportunity Analysis |
| 5.2. Immunostimulants |
| 5.2.1. Vaccines |
| 5.2.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.1.3. Market Opportunity Analysis |
| 5.2.2. Antibodies |
| 5.2.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.2.3. Market Opportunity Analysis |
| 5.2.3. Others |
| 5.2.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3.3. Market Opportunity Analysis |
| 6. Global Immunomodulators Market, By Application, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.1. Oncology |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Respiratory |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. HIV |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Others |
| 6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 7. Global Immunomodulators Market Forecast, By Region, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Europe |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Asia-Pacific |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Latin America |
| 7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Middle East and Africa |
| 7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 7.6. Global Immunomodulators Market - Opportunity Analysis Index, By Product, Application, and Region, 2024 - 2030 |
| 8. North America Immunomodulators Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 8.1. Product Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 8.1.1. Immunosuppressants |
| 8.1.1.1. Antibodies |
| 8.1.1.2. Calcineurin inhibitors |
| 8.1.1.3. Glucocorticoids |
| 8.1.1.4. Antimetabolites |
| 8.1.1.5. Others |
| 8.1.2. Immunostimulants |
| 8.1.2.1. Vaccines |
| 8.1.2.2. Antibodies |
| 8.1.2.3. Others |
| 8.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 8.2.1. Oncology |
| 8.2.2. Respiratory |
| 8.2.3. HIV |
| 8.2.4. Others |
| 8.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 8.3.1. USA |
| 8.3.2. Canada |
| 8.4. North America Immunomodulators Market - Opportunity Analysis Index, By Product, Application, and Country, 2024 - 2030 |
| 8.5. North America Immunomodulators Market Dynamics - Trends |
| 9. Europe Immunomodulators Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 9.1. Product Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1. Immunosuppressants |
| 9.1.1.1. Antibodies |
| 9.1.1.2. Calcineurin inhibitors |
| 9.1.1.3. Glucocorticoids |
| 9.1.1.4. Antimetabolites |
| 9.1.1.5. Others |
| 9.1.2. Immunostimulants |
| 9.1.2.1. Vaccines |
| 9.1.2.2. Antibodies |
| 9.1.2.3. Others |
| 9.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1. Oncology |
| 9.2.2. Respiratory |
| 9.2.3. HIV |
| 9.2.4. Others |
| 9.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 9.3.1. Germany |
| 9.3.2. UK |
| 9.3.3. France |
| 9.3.4. Spain |
| 9.3.5. Italy |
| 9.3.6. Russia |
| 9.3.7. Rest of Europe |
| 9.4. Europe Immunomodulators Market - Opportunity Analysis Index, By Product, Application, and Country, 2024 - 2030 |
| 9.5. Europe Immunomodulators Market Dynamics - Trends |
| 10. Asia-Pacific Immunomodulators Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 10.1. Product Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1. Immunosuppressants |
| 10.1.1.1. Antibodies |
| 10.1.1.2. Calcineurin inhibitors |
| 10.1.1.3. Glucocorticoids |
| 10.1.1.4. Antimetabolites |
| 10.1.1.5. Others |
| 10.1.2. Immunostimulants |
| 10.1.2.1. Vaccines |
| 10.1.2.2. Antibodies |
| 10.1.2.3. Others |
| 10.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1. Oncology |
| 10.2.2. Respiratory |
| 10.2.3. HIV |
| 10.2.4. Others |
| 10.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 10.3.1. China |
| 10.3.2. India |
| 10.3.3. Japan |
| 10.3.4. ASEAN |
| 10.3.5. Australia & New Zealand |
| 10.3.6. Rest of Asia-Pacific |
| 10.4. Asia-Pacific Immunomodulators Market - Opportunity Analysis Index, By Product, Application, and Country, 2024 - 2030 |
| 10.5. Asia-Pacific Immunomodulators Market Dynamics - Trends |
| 11. Latin America Immunomodulators Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 11.1. Product Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1. Immunosuppressants |
| 11.1.1.1. Antibodies |
| 11.1.1.2. Calcineurin inhibitors |
| 11.1.1.3. Glucocorticoids |
| 11.1.1.4. Antimetabolites |
| 11.1.1.5. Others |
| 11.1.2. Immunostimulants |
| 11.1.2.1. Vaccines |
| 11.1.2.2. Antibodies |
| 11.1.2.3. Others |
| 11.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1. Oncology |
| 11.2.2. Respiratory |
| 11.2.3. HIV |
| 11.2.4. Others |
| 11.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 11.3.1. Brazil |
| 11.3.2. Mexico |
| 11.3.3. Argentina |
| 11.3.4. Rest of Latin America |
| 11.4. Latin America Immunomodulators Market - Opportunity Analysis Index, By Product, Application, and Country, 2024 - 2030 |
| 11.5. Latin America Immunomodulators Market Dynamics - Trends |
| 12. Middle East and Africa Immunomodulators Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 12.1. Product Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1. Immunosuppressants |
| 12.1.1.1. Antibodies |
| 12.1.1.2. Calcineurin inhibitors |
| 12.1.1.3. Glucocorticoids |
| 12.1.1.4. Antimetabolites |
| 12.1.1.5. Others |
| 12.1.2. Immunostimulants |
| 12.1.2.1. Vaccines |
| 12.1.2.2. Antibodies |
| 12.1.2.3. Others |
| 12.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1. Oncology |
| 12.2.2. Respiratory |
| 12.2.3. HIV |
| 12.2.4. Others |
| 12.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 12.3.1. Gulf Cooperation Council (GCC) Countries |
| 12.3.2. Israel |
| 12.3.3. South Africa |
| 12.3.4. Rest of MEA |
| 12.4. MEA Immunomodulators Market - Opportunity Analysis Index, By Product, Application, and Country, 2024 - 2030 |
| 12.5. MEA Immunomodulators Market Dynamics - Trends |
| 13. Competition Landscape |
| 13.1. Strategic Dashboard of Top Market Players |
| 13.2. Company Profiles (Introduction, Financial Analysis, Product Offerings, Key Developments, Strategies, and SWOT Analysis) |
| 13.2.1. Hoffmann-La Roche Ltd (Basel, Switzerland) |
| 13.2.2. Novartis AG (Basel, Switzerland) |
| 13.2.3. Biogen (Massachusetts, U.S.) |
| 13.2.4. Teva Pharmaceutical Industries Ltd. (Petah Tikva, Israel) |
| 13.2.5. Amgen, Inc (California, U.S.) |
| 13.2.6. Bristol-Myers and Squibb Company (New York, U.S) |
| 13.2.7. Merck Sharp and Dohme Corp. (New jersey, U.S) |
| 13.2.8. Eli Lilly and Company (Indiana, U.S) |
| 14. Research Methodology |
| 15. Key Assumptions and Acronyms |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.